P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1

• Niels W.C.J. van de Donk,
• Alfred Garfall,
• Lotfi Benboubker,
• Katarina Uttervall,
• Kaz Groen,
• Laura Rosiñol Dachs,
• Caroline Hodin,
• Tara Stephenson,
• Danielle Trancucci,
• Alfredo Perales-Puchalt,
• Rachel Kobos,
• Arnob Banerjee,
• Maria-Victoria Mateos

Affiliations

Niels W.C.J. van de Donk

1 Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

Alfred Garfall

2 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, United States

Lotfi Benboubker

3 Hôpital Bretonneau, Centre Hospitalier Régionale Universitaire, Tours, France

Katarina Uttervall

4 Karolinska University Hospital, Stockholm, Sweden

Kaz Groen

1 Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands

Laura Rosiñol Dachs

5 Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain

Caroline Hodin

6 Janssen Research & Development BE, Antwerp, Belgium

Tara Stephenson

7 Janssen Research & Development, Spring House, United States

Danielle Trancucci

8 Janssen Research & Development, Raritan, United States

Alfredo Perales-Puchalt

7 Janssen Research & Development, Spring House, United States

Rachel Kobos

8 Janssen Research & Development, Raritan, United States

Arnob Banerjee

7 Janssen Research & Development, Spring House, United States

Maria-Victoria Mateos

9 University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain